WEBULL
WebtradeDownload

Is Summit Therapeutics (SMMT) Still Undervalued Following Mixed HARMONi Trial Results?

Simply Wall St · 2d ago

Summit Therapeutics (SMMT) is back in focus as investors watch an upcoming FDA decision on Ivonescimab plus chemotherapy for EGFR mutated lung cancer, following mixed HARMONi trial results.

Recent trading reflects that focus. At a latest share price of $17.83, Summit Therapeutics has booked a 7 day share price return of 12.85% and a 90 day share price return of 18.08%. However, the 1 year total shareholder return is down 6.94%, so short term momentum has picked up while longer term holders are still sitting on a very large 3 year total shareholder return of more than 8 times their original investment.

Spot other healthcare catalysts moving before their own decision dates by scanning the hand picked 36 healthcare AI stocks that sit alongside Summit Therapeutics on many investors' watchlists.

Summit Therapeutics has run hard into the FDA decision, yet the stock still trades well below both analyst targets and intrinsic value estimates. Where does a fair valuation really land after a move like this?

Most Popular Narrative: 41% Undervalued

On the analyst consensus Narrative on Simply Wall St, Summit Therapeutics screens as materially undervalued, with a fair value of about $30 per share against the latest close at $17.83. The gap reflects optimistic assumptions on ivonescimab, funding, and long range earnings power.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

See why 6 investors see Summit Therapeutics as 41% undervalued.

Result: Fair Value of $30 (UNDERVALUED)

Still, the single asset focus on ivonescimab and the need for clear overall survival gains in HARMONi leave Summit Therapeutics exposed to meaningful trial and regulatory risk.

Find out about the key risks to this Summit Therapeutics narrative.

Next Steps

Unsure about the article so far or already leaning one way in your own mind? Review the full balance of risk and reward now by reading the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Summit Therapeutics?

Do not stop with one ticker. Put Summit Therapeutics in context by lining it up against fresh ideas that match your own risk, income, and quality preferences.